Aarti Pharmalabs Q1 FY27 results: Revenue up 42%, PAT up 49% YoY; Rs 149 Cr capex approved
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 20.3 pts more than Nifty Microcap 250 and 20.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY27 results. Standalone revenue rose 42% YoY to Rs 534.6 cr; PAT up 49% to Rs 71.3 cr (EPS Rs 7.87). Consolidated revenue up 39% to Rs 535.8 cr; PAT up 65% to Rs 76.1 cr. Q1 FY25 figures restated for fair value loss on forward contract. Also approved Rs 149 crore capex for new Intermediate Block (405 KL capacity) for intermediates and CDMO customers. Rashesh Gogri to be MD from Oct 1; Hetal Gogri Gala shifts to Executive Director. Audit and CSR committees reconstituted.
Strong revenue and PAT growth signal robust demand. Rs 149 cr capex shows expansion focus. Key management reshuffle ahead.